Gland Pharma

Is this Pharma stock set for a comeback? Here’s why Motilal Oswal sees as much as 17% upside

Motilal Oswal has given Gland Pharma a ‘Buy’ rating with a Rs 2,310 target price, implying a 17% upside. The…

November 6, 2025 07:50 IST

Nifty Pharma index today, Nifty Pharma down, Indian pharma stocks fall

Pharma stocks crack, Nifty Pharma Index slips over 2% as Trump unveils 100% tariff: 3 key factors investors must watch

Nifty Pharma index drops over 2% after Trump unveils 100% tariff on drug imports – see which stocks are most…

September 26, 2025 11:50 IST

jefferies life insurance stock picks 2025 hdfc life icici prudential

3 ‘Buy’ recommendations by Motilal Oswal, with up to 18% upside potential

Motilal Oswal tips L&T, Gland Pharma, and Kotak Bank for up to 18% returns—see why these stocks could boost your…

September 25, 2025 14:25 IST

From SBI, Gensol Engineering, United Breweries to IRCON International- Here are 9 stocks to watch

Stocks to watch today, May 21: GIFT Nifty indicates a subdued start for domestic indices. Here are top stocks to…

May 21, 2025 06:38 IST

Gland Pharma Q4 Results: Net profit drops by 3% at Rs 186.54 crore on revenue decline on US market

Gland Pharma posted a 3 per cent decline in consolidated net profit to Rs 186.54 crore in the fourth quarter…

May 20, 2025 18:30 IST

USFDA gives nod to Gland Pharma’s generic formulation to treat glaucoma

According to IQVIA, the product had US sales of approximately USD 111.6 million for the twelve months ending December 2023.

December 3, 2024 14:40 IST

Q1FY25 results, Gland Pharma, Gland Pharma results, Gland Pharma Q1FY25 results, healthcare news, pharma news,

Q1FY25 results: Gland Pharma’s revenue rose by 16 percent to Rs. 1401.7 crore

Q1FY25 Results: The company also presented an outlook for Q2FY25 and said that lower activity levels are expected due to…

August 6, 2024 18:28 IST

Gland Pharma gets USFDA approval for its breast cancer drug

The Product has US sales of approximately $92 million for twelve months ending in February 2024, according to IQVIA.

April 8, 2024 17:27 IST

gland pharma, gland pharma quarterly results, gland pharma q3 results, industry

Gland Pharma posts Q3 profit fall on soaring employee costs

Gland Pharma’s total expenses jumped nearly 89% to Rs 12.99 billion, dragged by a more than three-fold climb in its…

February 14, 2024 17:59 IST

Gland Pharma stock jumps 20% today after revenue grows 41% on-year in Q1; should you buy, sell or hold GLAND?

Gland Pharma shares hit the upper circuit today after the company’s revenue grew 41% on-year to Rs 1,208.6 crore in…

August 8, 2023 12:16 IST

Glenmark, Glenmark pharmaceuticals, diabetes, blood sugar, healthcare news, pharma news,

Gland Pharma’s net profit falls 72 percent to Rs. 79 crore in Q4FY23

According to the company’s statement, core markets of US, Europe, Canada, Australia, and New Zealand accounted for 70% of revenue…

May 18, 2023 19:23 IST

viral infections, OPD cases, seasonal ailments, seasonal flu, health news,

Gland Pharma’s net profit declines 15 percent; Shares hit 52-week low

According to the company’s statement, its margin on earnings before interest, taxes, depreciation, and amortisation slipped to 35 percent from…

January 24, 2023 12:32 IST

Artificial Intelligence, AI, healthcare, healthtech, low-cost drugs, healthcare news,

Gland Pharma shares fall 4% on Cenexi acquisition report; should you buy, hold or sell?

Gland Pharma’s Singapore subsidiary Gland Pharma International PTE has entered into an agreement to acquire 100% of France-based contract development…

November 30, 2022 12:11 IST

Gland Pharma share price tanks 12% to hit 52-week low on weak Q1 results; stock may top Rs 3000 to rally 24%

At least two research and brokerage firms — Motilal Oswal Financial Services and YES Securities are bullish on Gland Pharma…

Updated: July 21, 2022 16:01 IST

Investor – Gland Pharma: Maintain ‘buy’; margins to be steady

Gland has a relatively limited launched portfolio in the Rest-of-World Market and India, which will expand to provide growth opportunities.

March 29, 2022 01:30 IST

Related News

Who is Alexandr Wang? 28-year-old hired for 14 billion US dollar by Mark Zukerberg to lead Meta superintelligence labs

Who is Alexandr Wang? 28-year-old hired for 14 billion US dollar by Mark Zuckerberg to lead Meta superintelligence labs

e-Passport launched in India: Who can apply, how to apply, application fee, benefits, key security upgrades and more

US Fed FOMC Meeting Live Updates: Fed cuts key interest rate by 25 bps, third deduction of 2025

Aadhaar card update December 2025: You can soon update your phone number from home online, no Aadhaar centre visit needed

Aadhaar card update: Here’s how to change your address after relocation

Indians Stuck as US Delays Thousands of H-1B Visa Interviews Amid New Screening Rules

‘Humiliation ritual for Indians’: Outrage over US postponing H-1B interviews

Kotak expects Nifty to rise 13% by 2026

Market2 hr ago

Kotak Securities predicts a 13% growth for Nifty 50 by December 2026 and has a positive outlook for gold and silver. The Indian market is expected to perform well due to better earnings and lower risks. The BFSI, IT, healthcare, and hospitality sectors are favored. However, the primary market is struggling to maintain higher levels due to outflows and focus on IPOs.

View all shorts